Home  /  Resource Library  /  Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Results of a study investigating the association of minimal residual disease on progression free survival in patients with CLL treated with ibrutinib.